Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South
Ist Teil von
Irish journal of medical science, 2017-11, Vol.186 (4), p.855-857
Ort / Verlag
London: Springer London
Erscheinungsjahr
2017
Quelle
MEDLINE
Beschreibungen/Notizen
Background
EGFR
mutated lung cancer represents a subgroup with distinct clinical presentations, prognosis, and management requirements. We investigated the survival, prognostic factors, and real-world treatment of NSCLC patients with
EGFR
mutation in clinical practice.
Methods
A retrospective review of all specimens sent for
EGFR
analysis from December 2009 to September 2015 was performed. Patient demographics, specimen type,
EGFR
mutation status/type, stage at diagnosis, treatment, response rate, and survival data were recorded.
Results
27/334 (8%) patient specimens sent for
EGFR
testing tested positive for a sensitising
EGFR
mutation. The median age was 65 years (40–85 years). Exon 19 deletion represented the most commonly detected alteration, accounting for 39% (
n
= 11). First-line treatment for those with Exon 18, 19, or 21 alterations (
n
= 24) was with an EGFR tyrosine kinase inhibitor (TKI) in 79% (
n
= 19). Objective response rate among these patients was 74% and median duration of response was 13 months (range 7–35 months).
Conclusion
The incidence of
EGFR
mutation in our cohort of NSCLC is 9% which is consistent with mutation incidence reported in other countries. The rate of
EGFR
mutation in our population is slightly below that reported internationally, but treatment outcomes are consistent with published data. Real-world patient data have important contributions to make with regard to quality measurement, incorporating patient experience into guidelines and identifying safety signals.